
Sign up to save your podcasts
Or


Alexion's top-brass has hit the exits amid an investigation into sales practices, and Ophthotech's future is in jeopardy following a high-profile phase 3 failure.
By The Motley Fool4.5
825825 ratings
Alexion's top-brass has hit the exits amid an investigation into sales practices, and Ophthotech's future is in jeopardy following a high-profile phase 3 failure.

3,217 Listeners

808 Listeners

944 Listeners

1,604 Listeners